Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1999 Oct;36(10):771–774. doi: 10.1136/jmg.36.10.771

Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression

S Borrego 1, M E Saez 1, A Ruiz 1, O Gimm 1, M Lopez-Alonso 1, G Antinolo 1, C Eng 1
PMCID: PMC1734238  PMID: 10528857

Abstract

Hirschsprung disease (HSCR) is a common genetic disorder presenting with functional intestinal obstruction secondary to enteric aganglionosis. HSCR can be familial or sporadic. Although five putative susceptibility genes have been identified, only germline mutations in the RET proto-oncogene account for a significant minority (up to 50%) of familial HSCR; 3% of sporadic HSCR in a population based series carry RET mutations. From 1998 to February 1999, we prospectively ascertained 64 cases of sporadic HSCR from the western Andalusia region. To determine if polymorphic sequence variants within RET could act as low penetrance predisposing alleles, we examined allelic frequencies at seven polymorphic loci in this population based series. Whether allele frequencies differed from those in the control population were determined by either chi-squared analysis or Fisher's exact test. For two sequence variants, A45A (c 135G→A) (exon 2) and L769L (c 2307T→G) (exon 13), the rarer polymorphic allele was over-represented among HSCR cases versus controls (p<0.0006). In contrast, two other polymorphisms, G691S (c 2071C→A) (exon 11) and S904S (c 2712C→G) (exon 15), were under-represented in the HSCR patients compared to controls (p=0.02). Polymorphisms in the RET proto-oncogene appear to predispose to HSCR in a complex, low penetrance fashion and may also modify phenotypic expression.


Keywords: polymorphism; low penetrance alleles; neurocristopathy; chromosome 10

Full Text

The Full Text of this article is available as a PDF (71.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angrist M., Bolk S., Thiel B., Puffenberger E. G., Hofstra R. M., Buys C. H., Cass D. T., Chakravarti A. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet. 1995 May;4(5):821–830. doi: 10.1093/hmg/4.5.821. [DOI] [PubMed] [Google Scholar]
  2. Attié T., Pelet A., Edery P., Eng C., Mulligan L. M., Amiel J., Boutrand L., Beldjord C., Nihoul-Fékété C., Munnich A. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet. 1995 Aug;4(8):1381–1386. doi: 10.1093/hmg/4.8.1381. [DOI] [PubMed] [Google Scholar]
  3. Badner J. A., Sieber W. K., Garver K. L., Chakravarti A. A genetic study of Hirschsprung disease. Am J Hum Genet. 1990 Mar;46(3):568–580. [PMC free article] [PubMed] [Google Scholar]
  4. Borrego S., Eng C., Sánchez B., Sáez M. E., Navarro E., Antiñolo G. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab. 1998 Sep;83(9):3361–3364. doi: 10.1210/jcem.83.9.5093. [DOI] [PubMed] [Google Scholar]
  5. Ceccherini I., Hofstra R. M., Luo Y., Stulp R. P., Barone V., Stelwagen T., Bocciardi R., Nijveen H., Bolino A., Seri M. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene. 1994 Oct;9(10):3025–3029. [PubMed] [Google Scholar]
  6. Edery P., Lyonnet S., Mulligan L. M., Pelet A., Dow E., Abel L., Holder S., Nihoul-Fékété C., Ponder B. A., Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature. 1994 Jan 27;367(6461):378–380. doi: 10.1038/367378a0. [DOI] [PubMed] [Google Scholar]
  7. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R. F., van Amstel H. K., Lips C. J., Nishisho I., Takai S. I. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996 Nov 20;276(19):1575–1579. [PubMed] [Google Scholar]
  8. Eng C., Mulligan L. M. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat. 1997;9(2):97–109. doi: 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  9. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999 Jan;17(1):380–393. doi: 10.1200/JCO.1999.17.1.380. [DOI] [PubMed] [Google Scholar]
  10. Eng C., Smith D. P., Mulligan L. M., Nagai M. A., Healey C. S., Ponder M. A., Gardner E., Scheumann G. F., Jackson C. E., Tunnacliffe A. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994 Feb;3(2):237–241. doi: 10.1093/hmg/3.2.237. [DOI] [PubMed] [Google Scholar]
  11. Gimm O., Neuberg D. S., Marsh D. J., Dahia P. L., Hoang-Vu C., Raue F., Hinze R., Dralle H., Eng C. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene. 1999 Feb 11;18(6):1369–1373. doi: 10.1038/sj.onc.1202418. [DOI] [PubMed] [Google Scholar]
  12. Laken S. J., Petersen G. M., Gruber S. B., Oddoux C., Ostrer H., Giardiello F. M., Hamilton S. R., Hampel H., Markowitz A., Klimstra D. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 1997 Sep;17(1):79–83. doi: 10.1038/ng0997-79. [DOI] [PubMed] [Google Scholar]
  13. Libert F., Cochaux P., Beckman G., Samson M., Aksenova M., Cao A., Czeizel A., Claustres M., de la Rúa C., Ferrari M. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet. 1998 Mar;7(3):399–406. doi: 10.1093/hmg/7.3.399. [DOI] [PubMed] [Google Scholar]
  14. Lyonnet S., Bolino A., Pelet A., Abel L., Nihoul-Fékété C., Briard M. L., Mok-Siu V., Kaariainen H., Martucciello G., Lerone M. A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. Nat Genet. 1993 Aug;4(4):346–350. doi: 10.1038/ng0893-346. [DOI] [PubMed] [Google Scholar]
  15. Mulligan L. M., Eng C., Attié T., Lyonnet S., Marsh D. J., Hyland V. J., Robinson B. G., Frilling A., Verellen-Dumoulin C., Safar A. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994 Dec;3(12):2163–2167. doi: 10.1093/hmg/3.12.2163. [DOI] [PubMed] [Google Scholar]
  16. Nakamura T., Ishizaka Y., Nagao M., Hara M., Ishikawa T. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol. 1994 Mar;172(3):255–260. doi: 10.1002/path.1711720305. [DOI] [PubMed] [Google Scholar]
  17. Passarge E. The genetics of Hirschsprung's disease. Evidence for heterogeneous etiology and a study of sixty-three families. N Engl J Med. 1967 Jan 19;276(3):138–143. doi: 10.1056/NEJM196701192760303. [DOI] [PubMed] [Google Scholar]
  18. Puffenberger E. G., Kauffman E. R., Bolk S., Matise T. C., Washington S. S., Angrist M., Weissenbach J., Garver K. L., Mascari M., Ladda R. Identity-by-descent and association mapping of a recessive gene for Hirschsprung disease on human chromosome 13q22. Hum Mol Genet. 1994 Aug;3(8):1217–1225. doi: 10.1093/hmg/3.8.1217. [DOI] [PubMed] [Google Scholar]
  19. Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., Pasini B., Bocciardi R., Lerone M., Käriäinen H. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature. 1994 Jan 27;367(6461):377–378. doi: 10.1038/367377a0. [DOI] [PubMed] [Google Scholar]
  20. Ruiz J., Blanché H., James R. W., Garin M. C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995 Sep 30;346(8979):869–872. doi: 10.1016/s0140-6736(95)92709-3. [DOI] [PubMed] [Google Scholar]
  21. Santoro M., Rosati R., Grieco M., Berlingieri M. T., D'Amato G. L., de Franciscis V., Fusco A. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene. 1990 Oct;5(10):1595–1598. [PubMed] [Google Scholar]
  22. Svensson P. J., Molander M. L., Eng C., Anvret M., Nordenskjöld A. Low frequency of RET mutations in Hirschsprung disease in Sweden. Clin Genet. 1998 Jul;54(1):39–44. doi: 10.1111/j.1399-0004.1998.tb03691.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES